Kochujang, fermented soybean-based red pepper paste, decreases visceral fat and improves blood lipid profiles in overweight adults

Youn-Soo Cha1*, Soo-Ran Kim1,2, Ji-Ae Yang1,2, Hyang-Im Back1,2, Min-Gul Kim2, Su-Jin Jung2, Won O Song4 and Soo-Wan Chae2,3*

Abstract: Health benefits of Kochujang (KCJ) and its bioactive compounds have been reported in several in vitro and animal studies. The aim of this study was to investigate the efficacy of KCJ supplementation on body composition and blood lipid profiles in overweight adults. The KCJ group showed a significant reduction in visceral fat (cm²) (p<0.05), although body weight (kg) and WHR did not change. Serum concentration of triglycerides and ApoB were decreased when compared to those of the placebo group. Kochujang supplementation (32 g/day) for 12 weeks in overweight adults showed anti-atherosclerotic and anti-obesogenic effects.

Trial registration: Clinical trials.gov Identifier: NCT01532375

Keywords: Kochujang (KCJ), Visceral fat, Triglyceride, Atherosclerosis index, Apolipoprotein

Background
The increasing westernized Korean dietary lifestyle, including frequently eating away from home, has favored foods that have not been a part of the traditional Korean diet [1]. The changing consumers’ demand for western food products and diminished traditional dietary lifestyle have overlapped with the prevalence of obesity and obesity-related chronic diseases in Korea [2,3]. Kochujang (KCI), a fermented soybean-based red pepper paste, has long been one of the most representative and commonly used seasonings in Korean cuisine as a sauce, dressing or seasoning for meat, vegetable dishes, stew and soup. The KCJ is produced by fermenting powder red peppers combined with powdered meju (fermented soybean powder), salt, malt-digested rice syrup, and rice flour for about six months. The fermentation process extends the storage period while increasing bioavailability of bioactive ingredients such as free amino acids, peptides, alcohols, organic acids, capsaicin and flavonoids [5,6]. KCJ has unique flavors of sweet and hot red pepper combined with savory soybean protein hydrolyzate and nucleic acids. In recent years, KCJ has gained its popularity outside Korea for its taste and health benefits derived from the several ingredients [7-16] that are produced by the fermentation process [17-22]. The functional substances either singularly or in combinations have exhibited anti-obesogenic, anti-oxidative, and anti-mutagenic properties.
in several in vitro experiments and in various murine models [7-16]. Anti-obesogenic and anti-atherogenic properties of fermented soy products have been demonstrated in obese adults [23], possibly through modulation of hepatic acyl-CoA synthase, carnitine palmitoyltransferase I, and acyl-CoA oxidase [24]. Recently Ludy and Mattes [25] reported that hedonically acceptable doses of red pepper altered thermogenesis and appetite. Their findings are consistent with previous reports of Reinbach et al [26] and others [27] who reported the alteration of appetite and energy balance as a result of red pepper or capsaicin intake. Lee et al [28] suggested that the alterations could be through changes in orexigenic and anorexigenic neuropeptides in hypothalamus.

With the epidemic of obesity and diabetes growing around the world, KCJ could be potentially effective in preventing and treating obesity and cardiovascular risks [16-20] if proven in humans. To date however no clinical trials of human feeding studies have been reported with KCJ supplementation. In the present randomized, double-blind, placebo-controlled clinical trial, we tested the hypothesis that KCJ supplementation decreases body fat and improves blood lipid profiles in overweight adults.

Subjects and methods

Study subjects

Healthy men and women volunteers, 19 to 65 years of age, with BMI ≥23 kg/m² and WHR of > 0.90 for men and >0.85 for women participated in the study. Excluded from the study were individuals with (1) lipid metabolic disorders; (2) >10% changes in body weight in the past 3 months; (3) cardiovascular disease such as arrhythmia, heart failure, myocardial infarction, and wearing pacemaker; (4) allergy or hypersensitivity to any of the ingredients in the test products; (5) history of reaction to any of the experimental products or of gastrointestinal diseases such as Crohn’s disease or gastrointestinal surgery (caecum or enterocele surgery); (6) participation in other clinical trials within the past 2 months; (7) abnormal hepatic liver function, renal disease such as acute/chronic renal failure, nephrotic syndrome; (8) use of anti-psychosis drug therapy within 2 months; (9) abnormal laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study; (10) history of alcohol or substance abuse; and (11) pregnancy or breastfeeding. All subjects willfully signed consent to participate in the study after receiving a detailed explanation of the purpose with research procedures. The research protocol was approved by the Institutional Review Board of Chonbuk National University Hospital's Clinical Trial Center for Functional Food.

Study design

At the onset of the study, each subject was interviewed for demographic information such as sex, date of birth, age and other lifestyle factors such as past smoking, drinking and medical histories. The subjects were divided into a KCJ group (n=30) and a placebo group (n=30) for the 12-week randomized, double-blind, placebo-controlled design. The KCJ supplement (32 g/day in pills) was equivalent to the usual daily intake of 39g wet weight of KCJ as consumed by Koreans. The KCJ used in the study was produced by the standardized manufacturing process and ingredients. Then a single batch KCJ was lyophilized and made into pills for the entire study (Imshil Herbal Medicine Co, Imsil, Republic of Korea). The placebo supplement had the same appearance and caloric contents without the principal ingredients that are present in KCJ (Table 1).

The subjects were instructed to maintain their usual lifestyle and activity levels and avoid other functional foods or dietary supplements during the 12-week study period. The subjects visited the clinic every 4 weeks for a total of five clinic visits (initial screening, and at weeks 0, 4, 8, 12) for monitoring and assessment of compliance with the protocol. At both the beginning and at the end of the 12-week intervention; anthropometric and biochemical parameters, computed tomography, vital signs, and dietary intakes were measured for both KCJ and placebo groups. At each visit to the clinic, the subjects were asked about adverse effects experienced, changes in physical activity, lifestyle, eating patterns, and pill compliance.

Table 1 Composition of Kochujang and placebo supplements (g/day)

|                  | Kochujang | Placebo |
|------------------|-----------|---------|
| Glutinous rice flour (g) | 10.9      | -       |
| Powdered red pepper(g)     | 11.9      | -       |
| Malt (g)                  | 5.2       | -       |
| Powdered fermented soybeans (g) | 4.7 | 1.1 |
| Spicy flavor powder(g)     | -         | 0.1     |
| Perfume of red pepper(g)   | -         | 0.3     |
| Honey(g)                  | -         | 1.4     |
| Caramel pigment(g)         | -         | 0.1     |
| Salt (g)                  | 5.2       | 1.4     |
| Soy sauce (g)              | 2.1       | 6.7     |
| Powdered cowpeas (g)       | 7.5       | 9.3     |
| Powdered cocoa (g)         | 2.5       | 1.4     |
| Powdered vegetable fat(g)  | -         | 6.3     |
| Wheat flour(g)             | -         | 13.1    |
| Red colors(g)              | -         | 1.5     |
| Total wet weight (g)       | 50        | 43      |
| Freeze-dried weight (g)    | 32        | 32      |
| Energy (kcal)              | 114       | 113.1   |
Anthropometric measurements
Height was measured using a DS-102 (JENIX, Korea). Weight, BMI, % body fat, body fat mass, muscle mass, and WHR were measured using bioelectrical impedance analysis (Inbody 3.0, Biospace Co., Seoul, Korea). At weeks 0 and 12, visceral fat, subcutaneous fat, and total fat were also measured using computed tomography (CT) scans and visceral to subcutaneous ratios (VSR) were calculated. Having lumbar vertebrae 4 (L4) as the center, five different regions between -20 and +20 were photographed for the abdominal fat area calculation. Visceral fat and subcutaneous fat were divided after setting the boundary between the abdominis and the peritoneum. After computing the numeric value of the total fat and visceral fat area, the subcutaneous fat area was calculated by subtracting the area of visceral fat from the total fat. The proportion was calculated as VSR.

Serum lipid, lipoprotein, atherosclerosis and index in glycaemic control factor
Fasted blood samples (>12 hr) were used to assess the blood lipid profiles: total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), free fatty acid (FFA), apolipoprotein AI (ApoA1), apolipoprotein B (ApoB), fasting plasma glucose, and HbA1c. Blood tests were conducted with a Hitachi 7600-110 analyzer (Hitachi High-Technologies Corp., Tokyo, Japan) by standard methods [23] used in the clinical laboratory of Chonbuk National University Hospital. Atherosclerosis Indices (AI) were measured by calculating the ratios (TC-HDL)/HDL, LDL/HDL and ApoB/ApoA1. The Cardiac Index (CI) was also calculated by the TC/HDL ratio.

Safety and dietary assessment
Safety measurements for the subjects were taken by electrocardiogram, hematology test and blood chemistry tests, i.e., white blood and red blood cell counts, hemoglobin, hematocrit, platelet count, total protein, albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine levels [29]. Pulse and blood pressure were measured at each visit after a 10-minute rest, using the OMRON74 digital blood pressure monitor (OMRON Corp., Tokyo, Japan). Each subject completed a 3-day dietary record for two weekdays and one weekend day in order to evaluate the energy intake and diet quality at each clinic visit. The twenty-four hour dietary intake data were analyzed by one dietitian throughout the study using Can-Pro 3.0 software (The Korean Nutrition Society, Seoul, Republic of Korea).

Statistical analysis
Statistical analyses were performed using SAS version 9.0 for Windows (SAS Institute, Cary, NC, USA) and SPSS for Windows, version 16.0 (SPSS, Chicago, USA). Data were expressed as the mean and standard errors (SE).

The statistical analysis for the main analysis were performed according to the intention-to-treat principle. Sample size for the study was based on the mean (SE) cm² of visceral fat difference between treatments in the previous study [30], -7.8 (3.6) cm² for the experimental group and +3.9 (6.4) cm² for the placebo group. It was estimated to provide 80% power to detect a difference between groups in visceral fat of 11.7(SD; 20.5) cm² with α = .05, using a 2-tailed t-test of the difference between means. The minimum sample size was determined to 48 participants (24 per group) by calculated, to allow for a 20% dropout rate a total of 60 participants were selected. Between subjects t-tests were calculated for all variables measures to determine whether there were changes associated with the treatment group. Within each treatment group, paired comparison t tests were calculated to test whether the change from 0-week to 12-week. Repeated measures mixed model analysis of variance was performed to see whether there were effects associated with time (with-person variable), treatment group (between-group variable), or the interaction of time and treatment group.

Results
Study subjects
The sampling and trial profiles are summarized in Figure 1 along with the number of subjects who completed the study. Out of 84 subjects pre-screened by interviews at the onset, 24 subjects did not meet the selection criteria either in laboratory tests and/or physical examinations. The remaining 60 subjects were randomly assigned to the KCJ (n=30) and placebo (n=30) groups. Four subjects (13%) from the KCJ group and three subjects (10%) from the placebo group failed to complete

![Figure 1 The Flow chart of the study.](http://www.nutritionandmetabolism.com/content/10/1/24)
the study. Five subjects were disqualified because of inadequate intake of the prescribed supplements, and two subjects voluntarily withdrew due to personal reasons. A total of 53 subjects (KCJ=26, placebo=27) completed this study.

General characteristics of subjects and dietary assessment
The KCJ and placebo groups were similar in baseline characteristics (Table 2). Significant differences between the two groups were observed in dietary intakes (calorie, carbohydrate, total protein) (Table 3). But no significant interactions (treatment*time) were observed in the dietary intake of macro-and micro-nutrients.

Body weight and components
Body weight and body composition data of both KCJ and placebo groups are summarized in the upper part of Table 4. After 12 weeks of KCJ supplementation, no significant changes were observed in body weight, BMI, body fat mass (kg), body fat (%) and WHR.

Table 2 Baseline characteristics of the subjects

| Variables                  | Kochujang group (n=30) | Placebo group (n=30) | P-value* |
|----------------------------|-------------------------|----------------------|----------|
| Age (y)                    | 42.1±1.3                | 43.0±2.2             | 0.786    |
| Sex (M/F)                  | 4/26                    | 3/27                 | 0.688    |
| Weight (kg)                | 68.0±1.5                | 57.0±2.3             | 0.431    |
| BMI (kg/m²)                | 26.7±0.4                | 27.4±0.8             | 0.383    |
| WHR                        | 0.91±0.005              | 0.90±0.006           | 0.242    |
| Visceral fat (cm²)         | 79.0±5.1                | 78.3±4.4             | 0.926    |
| Subcutaneous fat (cm²)     | 250.5±23.6              | 249.6±16.0           | 0.977    |
| SBP (mmHg)                 | 118.1±2.43              | 119.4±2.2            | 0.681    |
| DBP (mmHg)                 | 74.4±1.7                | 75.7±1.5             | 0.563    |
| Pulse rate (bpm)           | 68.7±1.9                | 71.4±1.8             | 0.216    |
| FPG (mg/dL)                | 83.3±1.6                | 81.6±1.5             | 0.449    |
| HbA1c (%)                  | 5.4±0.1                 | 5.4±0.1              | 0.894    |
| TC (mg/dL)                 | 192.4±4.7               | 195.3±6.0            | 0.649    |
| TG (mg/dL)                 | 118.4±10.2              | 120.0±12.1           | 0.703    |
| HDL (mg/dL)                | 52.0±1.7                | 52.5±2.1             | 0.822    |
| LDL (mg/dL)                | 123.6±4.4               | 125.1±5.8            | 0.835    |
| FFA (μEq/L)                | 612.4±40.5              | 549.5±33.9           | 0.239    |
| ApoA1 (g/dL)               | 1.44±0.03               | 1.45±0.04            | 0.770    |
| ApoB (g/dL)                | 0.86±0.03               | 0.87±0.04            | 0.944    |

1 Values are expressed as means ± SE.
* By independent t test.
BMI: body mass index, WHR: waist to hip ratio, TC: total cholesterol, TG: triglyceride, HDL: high density lipoprotein cholesterol, LDL: low density lipoprotein cholesterol, FFA: free fatty acid, ApoA1: Apolipoprotein A1, ApoB: Apolipoprotein B, SBP: systolic blood pressure, DBP: diastolic blood pressure, FPG: fasting plasma glucose.

Abdominal fat distribution by computerized tomography
Abdominal fat distributions measured by computerized tomography are shown in the lower part of Table 4. After 12-week of intervention, the KCJ group showed a significant reduction in visceral fat area compared to the placebo group. Furthermore, significant differences were observed in the visceral fat area from baseline to 12 weeks in both groups. The KCJ group attained a difference of -4.8 cm² whereas placebo group showed 0.4 cm² changes in the visceral fat area. Both the change in visceral/subcutaneous fat ratio decreased from baseline to 12 weeks (p<0.05). Furthermore, a significant interaction (time*group) were observed in the visceral fat area (p<0.038).

Blood lipid profiles and atherosclerosis index
As shown in Table 5, the mean difference in TG, ApoA1 and ApoB from baseline to 12 weeks were -17.9, -0.18 and -0.17, respectively in the KCJ group compared with 13.5, -0.14 and -0.12, respectively in the placebo group. A significant difference in the TG (p=0.026) level was observed between the two groups. Along with a significant interaction (time*group) in the difference of TG (p=0.042) between the two groups.

Apo B level showed no changes in the baseline and 12weeks in either group, however a significant difference was observed (p=0.049) between the two groups. While no significant interaction (time*group) were found in Apo B levels. There was no significant changes or differences observed in serum TC, HDL, LDL, ApoA1, ApoB and FFA level between the two groups. The changes in TC/HDL and (TC-HDL)/HDL ratio (Table 5) from baseline to 12-week were 0.42 and -0.32, in the KCJ group compared with -0.10 and -0.04, in the placebo group, however, these changes were not significant. ApoB/ApoA1 ratio also showed no changes between the baseline and 12weeks in either group, but a reduction in the ratio was observed in the KCJ groups from baseline to 12 weeks.

Safety measurements
The overall safety measures obtained before and after the intervention indicated no significant changes during the study (data not shown). The evaluations were also expanded to laboratory tests, electrocardiogram and vital signs (blood pressure, pulse) during the subjects’ visits.

Discussion
We hypothesized that KCJ supplementation for 12 weeks would reduce body fat and improve blood lipid profiles in overweight adults, as demonstrated in animal studies [20-22]. In this clinical trial, we found no significant effects on body weight (kg), body fat (%) or WHR after 12 weeks of KCJ supplementation. However, CT scans did reveal significant reductions in visceral fat area.
after KCJ supplementation. Furthermore, visceral fat area of the KCJ group was significantly lower than that of the placebo (Table 4). In our study we did not control the lifestyle of the subjects. Apart from the KCJ group, the placebo group also showed changes in certain parameter like total fat and subcutaneous fat, however these changes were not significant. Placebo causes psychological effects rather than the effect caused by its ingredients [30].

Many studies evaluate the effects of specific bioactive compounds or ingredients such as isoflavones, capsaicine, capsoids and red pepper power in subjects as adjuncts with additive effects of dietary intervention in a group of subjects following a weight loss program. This study took a different approach. The present study aimed to examine the biological outcome in humans resulting from the synergistic effects of functional compounds that constitute KCJ as a whole food, rather than those of the individual

### Table 3 Nutrient intakes of the Kochujang and placebo groups at the 0-wk and at 12-wk of the study

| Nutrients       | Kochujang group (n=30) | Placebo group (n=30) | P value<sup>1</sup> | P value<sup>2</sup> | P value<sup>3</sup> | P value<sup>4</sup> |
|-----------------|------------------------|----------------------|---------------------|---------------------|---------------------|---------------------|
|                 | 0wk    | 12wk   | Change*  | 0wk    | 12wk   | Change*  | 0.754 | 0.0172 | 0.028 | 0.680 |
| Calorie (kcal/d)| 1418.5±53.44 | 1393.1±92.9 | -25.4±115.5 | 1527.1±58.3 | 1548.1±79.8 | 20.9±89.9 | 0.816 | 0.0700 | 0.030 | 0.840 |
| Carbohydrate (g/d)| 222.8±8.2 | 208.2±10.3 | -14.6±14.3 | 242.8±11.0 | 233.1±12.8 | -9.5±16.5 | 0.867 | 0.853 | 0.040 | 0.823 |
| Total protein (g/d)| 34.7±3.8  | 34.6±3.8  | -0.1±4.7 | 37.6±1.7  | 37.3±3.5  | -0.3±3.4 | 0.973 | 0.955 | 0.027 | 0.273 |
| Fiber (g/d)      | 17.8±0.9 | 14.6±0.8 | -3.2±1.3 | 19.3±1.1 | 18.3±1.4 | -0.9±1.5 | 0.261 | 0.823 | 0.032 | 0.273 |
| Cholesterol (mg/d)| 210.5±22.8 | 249.4±27.5 | 39.0±27.7 | 204.3±14.5 | 280.0±26.4 | 75.7±31.8 | 0.385 | 0.940 | 0.448 | 0.429 |
| Na (mg/d)        | 3,630.4±2474 | 3,079.9±2253 | -550.4±305.5 | 3,665.9±1912 | 3,697.1±2204 | 31.1±280.3 | 0.168 | 0.316 | 0.164 | 0.170 |

All values are expressed as means ± SE.
P value<sup>1</sup>, t-test between changes of the Kochujang and placebo group : P value<sup>2,3,4</sup> time, group and interaction(time*group) effect of two-way repeated measure ANOVA, after adjusting for age and gender.

* Change = 12 wk – 0wk.
† Paired t-test between 0-wk and 12-wk (P<0.05).

### Table 4 Change of body weight, body composition, abdominal fat area, index in glycaemic control factor and blood pressure measurements at the 0-wk and 12-wk of the study

| Parameters                  | Kochujang group (n=30) | Placebo group (n=30) | P value<sup>1</sup> | P value<sup>2</sup> | P value<sup>3</sup> | P value<sup>4</sup> |
|-----------------------------|------------------------|----------------------|---------------------|---------------------|---------------------|---------------------|
|                             | 0wk    | 12wk   | Change*  | 0wk    | 12wk   | Change*  | 0.577 | 0.140 | 0.244 | 0.439 |
| Body weight (kg)            | 66.6±1.4 | 66.6±1.4 | 0.06±0.3 | 68.5±2.4 | 68.8±2.5 | 0.3±0.3 | 0.476 | 0.480 | 0.172 | 0.391 |
| Body fat mass (kg)          | 22.9±0.7 | 22.0±0.8 | -0.3±0.3 | 24.7±1.6 | 24.3±1.6 | -0.4±0.4 | 0.0±0.0 | 0.948 | 0.351 | 0.391 | 0.413 |
| Body fat (%)                | 33.4±0.8 | 33.8±0.7 | -4.0±0.4 | 34.7±0.9 | 34.6±0.9 | -0.1±0.2 | 0.606 | 0.692 | 0.248 | 0.544 |
| BMI                         | 26.5±0.4 | 26.5±0.8 | -0.1±0.4 | 27.8±0.9 | 27.6±0.9 | -0.1±0.1 | 0.606 | 0.692 | 0.248 | 0.544 |
| WHR                         | 0.91±0.006 | 0.893±0.009 | -0.1±0.1 | 0.90±0.007 | 0.90±0.001 | -0.1±0.1 | 0.351 | 0.692 | 0.475 | 0.274 |
| Total fat (cm²)             | 233.4±29.6 | 280.6±28.8 | -52.8±33.3 | 324.8±17.9 | 272.1±12.6† | -52.8±6.2 | 0.998 | 0.187 | 0.680 | 0.972 |
| Visceral fat (cm²)          | 81.1±5.5 | 76.2±5.6† | -4.8±3.3 | 78.4±4.8 | 78.9±4.3 | 0.4±2.1 | 0.043 | 0.001 | 0.974 | 0.038 |
| Subcutaneous fat (cm²)      | 252.3±27.1 | 204.4±26.7 | -47.9±33.4 | 246.4±17.0 | 193.2±11.1† | -53.2±6.6 | 0.875 | 0.107 | 0.649 | 0.869 |
| VSR                         | 0.37±0.03 | 0.42±0.03† | 0.05±0.2 | 0.36±0.01 | 0.44±0.03† | 0.08±0.01 | 0.218 | 0.001 | 0.849 | 0.302 |
| SBP (mmHg)                  | 117.3±2.4 | 120.3±2.4 | 2.9±2.4 | 119.3±2.3 | 119.7±2.4 | 0.4±1.5 | 0.367 | 0.260 | 0.706 | 0.447 |
| DBP (mmHg)                  | 74.5±1.9 | 75.4±1.9 | 0.9±1.9 | 75.6±1.6 | 76.9±2.1 | 1.3±1.5 | 0.880 | 0.877 | 0.548 | 0.813 |
| Pulse rate (bpm)            | 68.8±2.1 | 68.4±1.6 | -0.4±1.3 | 71.4±1.8 | 71.5±2.0 | 0.1±1.4 | 0.748 | 0.506 | 0.272 | 0.726 |
| FPG (mg/dl)                 | 84.6±1.6 | 80.7±1.8 | -3.8±1.1 | 81.6±1.6 | 79.6±1.9 | -1.9±1.0 | 0.217 | 0.056 | 0.454 | 0.188 |
| HbA1c (%)                   | 5.42±0.03 | 5.42±0.08 | 0.007±0.05 | 5.42±0.01 | 5.47±0.01 | 0.05±0.06 | 0.607 | 0.567 | 0.673 | 0.681 |

All values are expressed as means ± SE.
P value<sup>1</sup>, t-test between changes of the Kochujang and placebo group : P value<sup>2,3,4</sup> time, group and interaction(time*group) effect of two-way repeated measure ANOVA, after adjusting for age and gender.

* Change = 12 wk – 0wk.
† Paired t-test between 0-wk and 12-wk (P<0.05).
ANOVA, after adjusting for age and gender. Paired
† P value1, ApoB/ApoA1 density lipoprotein cholesterol)/high density lipoprotein cholesterol ratio; density lipoprotein cholesterol ratio, with an elevated ApoB/ApoA1 ratio with is considered to improve risk factors for cardiovascular disease. Significant decrease in visceral fat with concomitant doses of bioactive compounds, but did experience a very overall weight loss as seen in some studies using higher lifestyle. Our subjects did not experience a great degree of overweight subjects following a normal diet and supplementing a traditional food, KCJ, along with the diet components in KCJ. We therefore evaluated the effect of supplementing a traditional food, KCJ, along with the diet of overweight subjects following a normal diet and lifestyle. Our subjects did not experience a great degree of overall weight loss as seen in some studies using higher doses of bioactive compounds, but did experience a very significant decrease in visceral fat with concomitant improvements in risk factors for cardiovascular disease (Table 4). Visceral adiposity is known to be associated with an elevated ApoB/ApoA1 ratio with is considered to be a risk factor for metabolic syndrome [31]. Therefore, our results showing decreased visceral adiposity and decreased ApoB is consistent with a protective effect of KCJ against the development of metabolic syndrome. Our findings are similar to those in other studies in which adults (30–60 y of age) who ingested capsinoid (6 mg/d) orally lost abdominal fat and had increased fat oxidation [32]. In a study of obese college women who consumed red pepper extracts, the subjects lost both body weight and body fat [33]. The college women were closely monitored for their dietary intake through repeated education and weekly reminders. The close monitoring of dietary intake is believed to have resulted in changes in body weight and body fat composition. Other studies have also reported that daily supplementation of L-carnitine (300 mg) and isoflavones (400 mg) for 12 weeks decreased visceral fat [34]. Wu et al (2006) reported that isoflavon supplementation for one year resulted in no differences in body mass or body fat, but trunk fat mass decreased significantly [35]. Apart from single bioactive components supplement mediated anti-obesity effect, whole food like fermented soybean paste doenjang also reported to have anti-obesity effect in human obese subjects [36]. A Study using fermented kimchi powder as whole food mixed in animal diet proved to be beneficial in limiting weight gain in rodent models [37]. Although statistically insignificant, the changes in mean energy intake in the KCJ group decreased over 12 weeks while that in the placebo group increased (Table 3). It is thus possible that capsaicin or other bioactive components in KCJ might have functioned as appetite suppressants. Serum TG levels decreased in the KCJ supplemented group in contrast to those of the placebo group (Table 5). Similar results have been reported when overweight women were supplemented with L-carnitine and isoflavon. Capsaicin supplementation (0.014% wt or 3mg %) with a high fat diet in mice has also been reported to decrease blood TG, with no changes in TC levels [38]. In this study, KCJ supplementation resulted in beneficial effects on TG and ApoB(p<0.05). A study on healthy adults with Kimchi supplementation reported no changes in the LDL-C/HDL-C [39], but supplementation of isoflavon for 12 weeks significantly decreased the (TC-HDL)/HDL [34]. The profound effect of KCJ on visceral adiposity and atherogenic indices observed in the present study might have been mediated through one or more of the bioactive compounds in KCJ.

### Table 5 Serum lipid profiles of the Kochujang and placebo groups at the 0-wk and at 12-wk of the study

| Parameters                  | Kochujang group (n=30) | Placebo group (n=30) | Change | P value1 | P value2 | P value3 | P value4 |
|-----------------------------|------------------------|----------------------|--------|----------|----------|----------|----------|
|                            | 0wk                    | 12wk                 |        |          |          |          |          |
| Total cholesterol(mg/dL)    | 193.4±5.1              | 189.2±5.9            | -3.6±3.9 | 0.378    | 0.047    | 0.740    | 0.367    |
| Triglycerides(mg/dL)        | 112±5.9                | 94.6±5.8†            | -17.9±8.5 | 0.049    | 0.412    | 0.026    | 0.042    |
| HDL (mg/dL)                 | 52.3±1.9               | 51.2±1.9             | -1.07±1.5 | 0.012    | 0.100    | 0.923    | 0.670    |
| LDL (mg/dL)                 | 124.9±4.7              | 123.3±5.2            | -0.25±0.14 | 0.630    | 0.188    | 0.874    | 0.960    |
| Free fatty acid [μEq/L]     | 631.8±43.2             | 604.7±37.4           | -27.1±53.9 | 0.098    | 0.658    | 0.669    | 0.170    |
| ApoA1 (g/dL)                | 1.44±0.03              | 1.26±0.03†           | -0.18±0.03 | 0.145    | 0.002    | 0.729    | 0.216    |
| ApoB (g/dL)                 | 0.87±0.03              | 0.70±0.03†           | -0.17±0.02 | 0.088    | 0.76±0.04† | -0.12±0.02 | 0.049    | 0.001    | 0.540    | 0.025    |
| Atherosclerosis Indices     |                        |                      |        |          |          |          |          |
| TC/HDL                      | 3.8±0.1                | 3.4±0.2              | -0.42±0.2 | 0.093    | 0.935    | 0.460    | 0.357    |
| LDL/HDL                     | 2.4±0.1                | 2.2±0.1              | -0.25±0.1 | 0.630    | 0.976    | 0.671    | 0.752    |
| (TC-HDL)/HDL                | 2.8±0.1                | 2.5±0.2              | -0.32±0.2 | 0.046    | 0.253    | 0.975    | 0.454    | 0.297    |
| ApoB/ApoA1                  | 0.61±0.02              | 0.56±0.03†           | -0.05±0.01 | 0.61±0.03 | 0.60±0.03 | -0.01±0.02 | 0.296    | 0.075    | 0.240    | 0.593    |

All values are expressed as means ± SE.
HDL: High-density lipoprotein cholesterol, LDL: Low-density lipoprotein cholesterol, ApoA1: Apolipoprotein A1, ApoB: Apolipoprotein B, TC/HDL: total cholesterol/high density lipoprotein cholesterol ratio, LDL/HDL: low density lipoprotein/cholesterol; (TC-HDL)/HDL; total cholesterol - high density lipoprotein cholesterol/high density lipoprotein cholesterol ratio.
ApoB/ApoA1: Apolipoprotein B/Apolipoprotein A1.
P value1: t-test between changes of the Kochujang and placebo group: P value2,3,4 time, group and interaction (time*group) effect of two-way repeated measure ANOVA, after adjusting for age and gender.
* Change = 12 wk – 0 wk.
† Paired t-test between 0-wk and 12-wk (P<0.05).
such as capsaicin in red pepper, isoflavon glycosides, and peptides from fermented soy [40]. Capsaicin has been reported to upregulate lipolysis and thermogenesis while suppressing appetite [25–27]. Isoflavones such as genistein increases lipid oxidation with upregulated CPT-1 and activation of PPAR-α [21,41,42].

As the people with obesity and overweight tend to develop hypertension, the salt content of KCJ (Table 1) may be of concern. According to KNHANES study [43] (2010), the daily salt intake of all Koreans (including children and the elderly) averages 12.1g/day (4,878 mg Na). In the present study salt intake of the adult subjects from regular meals (~ 8.5 g/day) and KCJ supplementation (~ 6 g/day) was ~14.5 g/day (5,800 mg Na) which is 16.55% higher than the mean daily intake by all Koreans. Sodium excretion of the two groups in the present study, before and after the intervention, did not show any significant change.

KCJ could be helpful in utilizing it as ketchup or sauce in western diets. It can be used as an spicy ingredient in many dishes worldwide. Despite the concern of salt content of KCJ, we observed the therapeutic benefits of KCJ in our adult subjects. These findings suggest that KCJ may have the potential to be developed as a whole food, nutraceutical or functional supplement for the management of obesity in some population.

Conclusion
Decreased visceral adiposity and improved atherosclerosis indices were observed after overweight adults received KCJ supplementation for 12 weeks. The unique strength of this study was the observation of biological effect of KCJ, a whole food, in free-living overweight adults. However, the mechanisms responsible for these observed effects are yet to be elucidated.

Competing interests
None of the above authors have conflicts of interest.

Authors’ contributions
All authors had participated in this work with substantive contributions. Soo-Ran Kim, Ji-Ae Yang, Hyoung-im Back, and Min-Gui Kim had the responsibility to carry out the daily responsibility of the RCT projects. Drs. Soo-Wan Chae, Won O Song, and Youn-Soo Cha had participated in biochemical analysis, to carry out the statistical analysis. Drs. Soo-Wan Chae, Ran Kim Ji-Ae Yang, Hyang-Im Back, and Min-Gul Kim had the responsibility

Funding sources
This study was supported by grants from the Ministry for Food, Agriculture, Forestry and Fisheries (20080101496-00) and research funds of Chonbuk National University in 2011.

Author details
1Department of Food Science and Human Nutrition, Chonbuk National University, Obesity Research Center, 664-14 Dukjin-Dong 1-Ga, Jeonju, Jeonbuk 561-756, Republic of Korea. 2Clinical Trial Center for Functional Foods, Chonbuk National University Hospital, 634-18, Geumnam-dong, Deokjin-su, Jeonju, Jeonbuk 561-172, Republic of Korea. 3Department of Pharmacology, Chonbuk National University, Medical School, Jeonju, Jeonbuk 561-172, Republic of Korea. 4Department of Food Science and Human Nutrition, Michigan State University, East Lansing, MI 48824-1224, USA.

Received: 5 November 2012 Accepted: 21 February 2013
Published: 26 February 2013

References
1. Yu KU: Analysis of the relationship between dietary fiber intake and food habits in the korean adult population. The Korean J Nutr 2008, 41:19.
2. Jin EH: A study on health related action rates of dietary guidelines and pattern of dietary in middle-aged women. J Korean Soc Health Inform Health Stat 2009, 34:12.
3. Park S, Park CH, Jang IS: Antecedent intake of traditional Asian-style diets exacerbates pancreatic beta-cell function, growth and survival after Western-style diet feeding in weaning male rats. J Nutr Biochem 2006, 17:307–318.
4. Kim J: Biologically active components of soy-fermented foods. Korean Soybean Digest 2002, 127:1.
5. Oh, L; Kim Y, Shin D: Changes in microorganisms, enzyme activities, and gas formation by the addition of mustard power on Kochujang with different salt concentration. Food Sci Biotechnol 2006, 15:298–302.
6. Kwon DY, Hong SM, Ahn IS, Kim YS, Shin DW, Park S: Kochujang, a Korean fermented red pepper plus soybean paste, improves glucose homeostasis in 90% pancreatectomized diabetic rats. Nutrition 2009, 25:790–799.
7. Kwon S, Lee K, Im K, Kim S, Park K: Effects of capsaicin on lipid metabolism in rats fed a high fat diet. J Nutr 1986, 116:1272–1278.
8. Kang JH, Goto T, Han IS, Kawada T, Kim YM, Yu R: Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet. Obesity (Silver Spring) 2010, 18:780–787.
9. Ahn IS, Do MS, Kim SQ, Jung HS, Kim YI, Kim HJ, Park KY: Antiobesity effect of Kochujang (Korean fermented red pepper paste) extract in 3T3-L1 adipocytes. J Med Food 2006, 9:15–21.
10. Watanabe T, Kawada T, Kato T, Harada T, Iwai K: Effects of dietary fiber intake and food on weight and lipid levels of adipose tissues and serum in rats fed a high-fat diet. J Nutr Sci Vitaminol 2006, 52:47–54.
11. Shin D, Kim D, Choi U, Lim M, An E: Anti-inflammatory effects of red pepper (Capsicum baccatum) on carrageenan- and antigen-induced inflammation. J Pharm Pharmacol 2008, 60:473–478.
12. Choo J, Shin H: Body-fat suppressive effects of capsaicin through β-adrenergic stimulation in rats fed a high-fat diet. Korean J Nutr 1999, 32:553–559.
13. Cornwell T, Coleck W, Raskin I: Dietary phytoestrogens and health. Phytochemistry 2004, 65:995–1016.
14. Choi YM, Suh HJ: Pharmacological effects of fermented red pepper. Phyther Res 2004, 18:884–888.
15. Kwon S, Lee K, Im K, Kim S, Park K: Weight Reduction and Lipid Lowering Effects of Korean Traditional Soybean Fermented Products. J Korean Soc Food Sci Nutr 2006, 35:1194–1199.
16. Shin D, Kim D, Choi U, Lim D, Lim M: Studies on the physicochemical characteristics of traditional Kochujang, Korean J Food Sci Technol 1996, 28:157–161.
17. Jeong D, Shin D, Song M: Studies on the physicochemical characteristics of Sunchang traditional Kochujang, Korean J Food Cult 2001, 16:260–267.
18. Shin D, Kim D, Choi U, Lim M, An E: Taste components of traditional Kochujang prepared with various raw materials. Korean J Food Sci Technol 1997, 29:913–918.
19. Rhee S, Kong K, Jung K, Park K: Decreasing effects Kochujang on body weight and lipid levels of adipose tissues and serum in rats fed a high-fat diet. J Food Sci Technol 2003, 32:862–866.
20. Soo B, Seong SH, Kwon DY, Sohn HS, Cha YS: Fermented Kochujang supplementation shows anti-obesity effects by controlling lipid metabolism in C57BL/6J mice fed high fat diet. Food Sci Biotechnol 2008, 17:336–342.
21. Choo J: Anti-obesity effects of Kochujang in rats fed on high fat diet. The Korean J Nutr 2000, 33:787–793.
22. Back Hl, Kim SR, Yang JA, Kim MG, Chae SW, Cha YS: Effects of Chungkookjang supplementation on obesity and atherosclerotic indices in overweight/obese subjects; a 12-week, randomized, double-blind, placebo-controlled clinical trial. J Med Food 2011, 14:532–537.
23. Soh JR, Shin DH, Kwon DY, Cha YS: Effect of Cheonggukjang supplementation upon hepatic acyl-CoA synthase, carnitine palmitoyltransferase I, acyl-CoA oxidase and uncoupling protein 2 mRNAs levels in C57BL/6J mice fed with high fat diet. Genes Nutr 2008, 3:265–369.
25. Ludy MJ, Mattes RD: The effects of hedonically acceptable red pepper doses on thermogenesis and appetite. *Physiol Behav* 2011, 102:251–258.

26. Reinbach HC, Smeets A, Martinussen T, Moller P, Westerterp-Plantenga MS: Effects of capsaicin, green tea and CH-19 sweet pepper on appetite and energy intake in humans in negative and positive energy balance. *Clin Nutr* 2009, 28:260–265.

27. Yoshioka M, St-Pierre S, Drapeau V, Dionne I, Doucet E, Suzuki M, Tremblay A: Effects of red pepper on appetite and energy intake. *Br J Nutr* 1999, 82:115–123.

28. Lee CH, Choi JH, Hwang K, Yoo KY, Li H, Park OK, Yan B, Shin HC, Won MH: Immunohistochemical Changes in Orexigenic and Anorexigenic Neuropeptides in the Rat Hypothalamus after Capsaicin Administration. *J Vet Med Sci* 2009, 71:1337–1342.

29. Friedman JH, Dubinsky R: The placebo effect. *Neurology* 2008, 71:25–26.

30. Lee YH, Choi JH, Lee KW, Kim DJ: Apolipoprotein B/A1 ratio is associated with free androgen index and visceral adiposity and may be an indicator of metabolic syndrome in male children and adolescents. *Clin Endocrinol (Oxf)* 2011, 74:579–586.

31. Snitker S, Fujishima Y, Shen HQ, Ott S, Pi-Sunyer X, Furuhata Y, Sato H, Takahashi M: Effects of novel capsinoid treatment on fatness and energy metabolism in humans: possible pharmacogenetic implications. *Am J Clin Nutr* 2009, 89:45–50.

32. Chang U, Kim J, Suh H, Oh S: Weight reduction effect of extract of fermented red pepper on female college students. *J Korean Soc Food Sci Nutr* 2003, 32:479–484.

33. Gwak JH, Lee JH, Lee SJ, Prak HW, Kim Y, Hyun YJ: The effect of L-carnitine and isoflavone supplementation on weight reduction and visceral fat accumulation in overweight women. *Korean J Nutr* 2007, 40:59.

34. Wu J, Oka J, Tabata I, Higuchi M, Toda T, Fuku N, Ezaki J, Sugiyama F, Suzuki M: Effects of white bean extract. *Nutr Res* 2009, 32:115–126.

35. Oi Y, Kawada T, Watanabe T, Iwao K: Induction of capsaicin-hydrolyzing enzyme-activity in rat-liver by continuous oral-administration of capsaicin. *J Agric Food Chem* 1992, 40:467–470.

36. Choi S, Kim H, Kwon M, Baek Y, Song Y: The effect of Kimchi pill supplementation on plasma lipid concentration in healthy people. *J Korean Soc Food Sci Nutr* 2001, 30:103–920.

37. Kwon DY, Daily JW, Kim HJ, Park S: Antidiabetic effects of fermented soybean products on type 2 diabetes. *Nutr Res* 2010, 30:1–13.

38. Kim S, Shin HJ, Kim SY, Kim JH, Lee YS, Kim DH, Lee MO: Genistein enhances expression of genes involved in fatty acid catabolism through activation of PPARα. *Mol Cell Endocrinol* 2004, 220:51–58.

39. Yang JY, Lee SJ, Park HW, Cha YS: Effect of genistein with carnitine administration on lipid parameters and obesity in C57Bl/6J mice fed a high-fat diet. *J Med Food* 2006, 9:459–467.

40. Jang KH, YS, Lee SW, Lee JW, Kim NY, Jin DR: Korea’s health and Welfare trends. Seoul 2010, 128:128.